General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-13 | 2024-09 | 0.13 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 0.08 | 0.13 | 0.05 | 62.50% |
2024-05-09 | 2024-03 | 0.05 | 0.08 | 0.03 | 60.00% |
2024-02-28 | 2023-12 | 0.02 | 0.04 | 0.02 | 100.00% |
2023-11-08 | 2023-09 | -0.01 | 0.01 | 0.02 | 200.00% |
2023-08-09 | 2023-06 | -0.02 | -0.02 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-09 | Raymond James | Upgrade | Strong Buy | Strong Buy |
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-03-26 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-07 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-02 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-18 | ELMS STEVEN A | Director | 0.00 | Sale |
2024-02-25 | FINGER ALISON CECILY | Director | 24.04K | Stock Award(Grant) |
2024-02-25 | FONG BRYANT E. | Director | 83.94K | Stock Award(Grant) |
2024-08-26 | GROSSMAN ADAM S | Chief Executive Officer | 3.78M | Sale |
2024-08-28 | GROSSMAN JERROLD B | Director | 560.01K | Sale |
2024-09-08 | GUIHEEN LAWRENCE P | Director | 154.94K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 16.37M | 60.39M | 7.28% |
2023-06-29 | Vanguard Group Inc | 12.45M | 45.92M | 5.53% |
2023-06-29 | Perceptive Advisors Llc | 11.90M | 43.91M | 5.29% |
2023-06-29 | State Street Corporation | 10.51M | 38.80M | 4.67% |
2023-06-29 | Stonepine Capital Management, LLC | 8.79M | 32.45M | 3.91% |
2023-06-29 | Nuveen Asset Management, LLC | 8.56M | 31.58M | 3.81% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 6.41M | 23.66M | 2.85% |
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 6.05M | 23.30M | 2.69% |
2023-08-30 | iShares Russell 2000 ETF | 4.77M | 18.35M | 2.12% |
2023-06-29 | Vanguard Extended Market Index Fund | 2.90M | 10.70M | 1.29% |
2023-06-29 | Invesco Main Street Small Cap Fund | 2.57M | 9.49M | 1.14% |
2023-06-29 | College Retirement Equities Fund-Stock Account | 2.08M | 7.68M | 0.93% |
History $IBIO,was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. This will be remembered for the rest of our lives.also $IBIO made money from all past pandemics, $IBIO shares prices in last pandemics 15$ to 55$ ,today $IBIO is going up
History $IBIO made money from all pandemics,was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come.
It’s the $1.99 special. Get it while you can!
ADMA CEO Adam Grossman said in a conference call in September that he expects revenues to be higher in the second half of 2020 than in the first half. I believe him. Hopefully Q3 results will surprise.
History $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. This will be remembered for the rest of our lives. Also If people Will take the COVID-19 vaccine,they will trust and prefer a vaccine made of plants$IBIO has the best and most advanced technology at the moment
Hopefully revenue will beat estimates.
https://www.google.com/amp/s/www.marketbeat.com/instant-alerts/nasdaq-adma-consensus-analyst-rating-2020-10/amp/
Without a news catalyst this will swing back up to 2.60 and fall back to 2.20 again.
History $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. This will be remembered for the rest of our lives. Also If people Will take the COVID-19 vaccine,they will trust and prefer a vaccine made of plants$IBIO has the best and most advanced technology at the moment
I remember the week leading up to Q2 this year ADMA ran up in price. History repeats itself.
Last month I sold my shares at 3.60 at the open and bought them back at 2.75 thinking it was a great deal. I never expected this stock to drop to 1.99. I fully expect ADMA to relive some of its old glory with some positive news. Holding long and strong.
ADMA collected plasma and conducted R&D to help the Plasma Alliance develop this therapy.
https://www.biopharmadive.com/news/takeda-nih-hyperimmune-plasma-coronavirus-trial/586761/
ADMA is working with the Plasma Alliance on this COVID-19 Hyperimmune medicine. They are part of an alliance of 11 plasma companies.
https://www.prnewswire.com/news-releases/first-patient-enrolled-in-nih-phase-3-trial-to-evaluate-potential-covid-19-hyperimmune-medicine-301148902.html
ADMA CEO, Founder and President Adam Grossman in a Plasma Alliance video.
https://www.covig-19plasmaalliance.org/videos/ALLIANCE_v5.mp4
Biotech Penny Stocks To Watch #2: ADMA Biologics Inc.
Shares of ADMA Biologics Inc. (NASDAQ: ADMA) is another one of the biotech penny stocks that have been on the radar for a few weeks now. It was also one of the top penny stocks on Robinhood to watch at the start of the week. If you recall, there was a big boom in plasma stocks for a brief period this summer. A number of these stocks took off in light of comments made by the U.S. President at the time. Last month ADMA launched a COVID-19 ImmunoRank Neutralization MICRO-ELISA. It’s a fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma.
With a recent surge of attention on coronavirus penny stocks, ADMA is back in the mix. Trading volumes have picked up over the last few weeks and shares have climbed nearly 30%. One of the points of resistance for the stock has been its 50 day moving average. As you can see in the stock chart for the last 6 months, the 50-Day (in yellow) has been a point where ADMA stock has tested and failed at, with a few exceptions. Obviously, it wasn’t able to hold those levels and came back down soon after.
What’s brought a bigger focus on the company as of late has been some analyst actions. Earlier this month, analysts at Raymond James maintained their rating of Outperform on the penny stock. However, the firm did lower its price target to $7 from $9. Given these recent developments, the sympathy momentum from coronavirus, and key technical levels, can ADMA stock continue higher in October?
“Investors should also keep an eye on sector updates as ADMA has historically followed its peers on positive news.”
https://oracledispatch.com/2020/10/06/adma-biologics-inc-nasdaqadma-finding-strong-support/
When the trial finally starts it could be a catalyst. ADMA assisted the Takeda led plasma alliance with plasma collection and research and development. This article is sleazy 3 weeks old so news should be forthcoming.
https://kfgo.com/2020/09/17/takeda-led-covid-19-plasma-product-to-begin-trial-this-month/